Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price fell 22.9% during trading on Friday . The stock traded as low as C$0.18 and last traded at C$0.19. 504,239 shares were traded during mid-day trading, a decline of 5% from the average session volume of 530,580 shares. The stock had previously closed at C$0.24.
Hemostemix Stock Performance
The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The company has a 50 day moving average of C$0.19 and a 200 day moving average of C$0.12. The firm has a market cap of C$28.42 million, a price-to-earnings ratio of -5.69 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- How to Profit From Growth Investing
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- Consumer Discretionary Stocks Explained
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- Using the MarketBeat Stock Split Calculator
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
